Please login to the form below

Not currently logged in
Email:
Password:

progressive supranuclear palsy

This page shows the latest progressive supranuclear palsy news and features for those working in and with pharma, biotech and healthcare.

Spinraza lifts Biogen ahead of Alzheimer’s data

Spinraza lifts Biogen ahead of Alzheimer’s data

enrolment in phase 2 studies of new MS therapy opicinumab and BIIB092 for progressive supranuclear palsy.

Latest news

  • Celgene bulks up pipeline again with $2.1bn Prothena deal Celgene bulks up pipeline again with $2.1bn Prothena deal

    The three targets at the centre of the collaboration with Ireland-based Prothena include: tau protein, already a focus in Alzheimer’s research and other conditions like progressive supranuclear palsy (PSP);

  • AbbVie takes anti-tau drug into phase II for Alzheimer's AbbVie takes anti-tau drug into phase II for Alzheimer's

    drugs. The antibody - called ABBV-8E12 - is being tested in two phase II trials, one in patients with early Alzheimer's and a second in progressive supranuclear palsy (PSP), a rare ... We see potential in ABBV-8E12 and tau-focused approaches to

  • AbbVie and C2N take tau antibody into clinic AbbVie and C2N take tau antibody into clinic

    AbbVie and C2N take tau antibody into clinic. Treatment being assessed for a progressive neurodegenerative disorder. ... The first-in-class therapy - called C2N-8E12 or ABBV-8E12 - is being tested in patients with the rare neurodegenerative disorder

  • BMS buys Alzheimer's player iPierian in $725m deal BMS buys Alzheimer's player iPierian in $725m deal

    IPN007 is being developed in the first instance for progressive supranuclear palsy (PSP), a serious neurodegenerative disorder that progresses much more quickly than Alzheimer's but is also characterised by tau

  • CNS drug wins orphan status

    CNS drug wins orphan status. Drug-development company Mithridion has won orphan status from the US Food and Drug Administration for a potential treatment for brain disease progressive supranuclear palsy. ... The clinical-stage drug-development company

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
What everyone forgets about good organisational change in pharma
Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....
Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies
Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST...

Infographics